Our group specialises in CD8+ T cell biology and antigen processing and presentation, particularly in relation to the development of cross-protective immune responses to the influenza virus.
Our group studies the molecular mechanisms underlying Gram-negative bacterial infections to develop antibacterial drugs that are not susceptible to existing resistance mechanisms.
Our group works on protection of humans and crops from pathogens. We do this by studying natural defences of plants, and the biology of the pathogens themselves.
Our group studies AAA+ proteases, responsible for general and regulated protein turn over in bacteria and in some organelles of eukaryotes.
Our group uses single domain antibodies that have been developed from sharks to identify novel therapeutics against a number of chronic diseases.
Our group examines how viruses hijack cellular defence systems to ensure their own proliferation and survival.
Our group studies the structure, function, regulation and inhibition of essential oligomeric enzymes such as dihydrodipicolinate synthase (DHDPS), from the lysine biosynthesis pathway of bacteria.
Our group studies the machinery that control how dying cells can disassemble into smaller pieces, and the importance of cell disassembly in disease settings, to identify new drugs to control this process.
Our group researches the molecular basis of apoptosis regulation during heart failure, sepsis and in chemo resistance.
Our group examines the structure-function relationship of essential bacterial and plant enzyme targets to guide the design of novel antibiotics and herbicides.
Our group studies the use of bacteriophage as alternatives to antibiotics. We also examine the personalization of medicine to fit a patient's genetic profile, and patient management of medication in the treatment of chronic disease.
Our group researches enzymes, called proteases, which operate at the interface between a host, such as a human being and microbes that cause disease.